Nova Gorica – European Clinical Trials Information Network

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Mon, 03 Aug 2026 10:42:15 +0000

This study is looking at people with type 2 diabetes whose blood sugar levels are not well controlled with their current medication. Type 2 diabetes is a condition where the body does not properly use insulin, a hormone that helps control blood sugar levels. The study will test different combinations and doses of medications given as injections under the skin. These medications include cagrilintide, semaglutide, a combination of both called CagriSema, and placebo. Some participants may also continue taking their regular diabetes medications, which could include metformin taken by mouth, with or without a type of medication called an SGLT2 inhibitor such as dapagliflozin.

The main goal of the study is to see how well CagriSema works at lowering blood sugar levels compared to semaglutide alone, as measured by a blood test called HbA1c that shows average blood sugar over several months. The study will also look at how these medications affect body weight, blood pressure, cholesterol levels, and other health measurements. Researchers want to understand if the combination medication works better than the individual medications at helping people reach target blood sugar levels and lose weight. The study will also measure how much time blood sugar levels stay within a healthy range using a continuous glucose monitor, which is a small device that tracks sugar levels throughout the day.

Participants will receive their assigned treatment for 68 weeks, with the entire study lasting about 75 weeks. During this time, they will have regular visits to check their blood sugar, weight, blood pressure, and overall health. The study will also ask participants questions about their quality of life and satisfaction with their diabetes treatment. Safety will be carefully monitored throughout the study, including checking for side effects and episodes of low blood sugar, which can occur when blood sugar drops too low and may cause symptoms like shakiness or confusion.

Study on AVP-786 for Treating Agitation in Alzheimer’s Dementia Patients

Mon, 03 Aug 2026 10:23:50 +0000

This clinical trial is focused on studying the treatment of agitation in patients with dementia of the Alzheimer’s type. The treatment being tested is a medication called AVP-786, which is a combination of two active substances: quinidine sulfate and deudextromethorphan hydrobromide. The study will compare the effects of AVP-786 to a placebo to understand its effectiveness, safety, and how well patients can tolerate it.

The purpose of the study is to evaluate how well AVP-786 works in reducing agitation symptoms in patients with Alzheimer’s-related dementia. Participants in the study will receive either the AVP-786 medication or a placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will take the medication in capsule form by mouth. The study will last for a set period, during which participants will be monitored for any changes in their symptoms and any side effects they may experience. The goal is to determine if AVP-786 can help manage agitation in patients with Alzheimer’s-related dementia more effectively than a placebo.

ZDRAVSTVENI DOM Osnovno varstvo Nova Gorica

Tue, 02 Jun 2026 09:57:20 +0000

Nevrološka ambulanta Kromberk

Thu, 30 Apr 2026 09:19:58 +0000